SyntekaBio Inc
SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, di… Read more
SyntekaBio Inc (226330) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.169x
Based on the latest financial reports, SyntekaBio Inc (226330) has a cash flow conversion efficiency ratio of -0.169x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.01 Billion) by net assets (₩11.90 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SyntekaBio Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how SyntekaBio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
SyntekaBio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SyntekaBio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wearable Devices Ltd.
NASDAQ:WLDSW
|
-0.778x |
|
It's Skin Co Ltd
KO:226320
|
0.013x |
|
Crest Ventures Limited
NSE:CREST
|
0.015x |
|
Batavia Prosperindo Int
JK:BPII
|
0.016x |
|
Equity Metals Corporation
OTCQB:EQMEF
|
-0.520x |
|
1480
TWO:1480
|
0.090x |
|
RSWM Limited
NSE:RSWM
|
0.229x |
|
The Brooker Group Public Company Limited
BK:BTC
|
0.002x |
Annual Cash Flow Conversion Efficiency for SyntekaBio Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of SyntekaBio Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩24.94 Billion | ₩-10.51 Billion | -0.421x | -62.87% |
| 2023-12-31 | ₩31.23 Billion | ₩-8.08 Billion | -0.259x | +4.38% |
| 2022-12-31 | ₩31.46 Billion | ₩-8.51 Billion | -0.271x | -23.73% |
| 2021-12-31 | ₩27.63 Billion | ₩-6.04 Billion | -0.219x | -94.57% |
| 2020-12-31 | ₩41.54 Billion | ₩-4.67 Billion | -0.112x | -57.95% |
| 2019-12-31 | ₩46.11 Billion | ₩-3.28 Billion | -0.071x | +95.06% |
| 2018-12-31 | ₩1.64 Billion | ₩-2.37 Billion | -1.441x | -261.66% |
| 2017-12-31 | ₩-2.79 Billion | ₩-2.49 Billion | 0.891x | -- |